You are here

  • Home
  • Archive
  • Volume 80, Issue 1
  • EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Citation Tools

Article menu
Recommendation
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kostine M, Finckh A, Bingham CO, et al
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Annals of the Rheumatic Diseases 2021;80:36-48.